LINDSEY STACY: Open Payments
NPI 1316699028 · JONESBORO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$644 in 32 payments from 11 companies in 2025. Trend: 2023 $541 · 2024 $534 · 2025 $644
Food & beverage: $644
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation | 5 | $99 |
| Alkermes, Inc. | 4 | $99 |
| Janssen Pharmaceuticals, Inc | 4 | $87 |
| Neurocrine BioSciences, Inc. | 5 | $82 |
| Biogen, Inc. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| E.R. Squibb & Sons, L.L.C. | 2 | $48 |
| ABBVIE INC. | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
Products named: INVEGA SUSTENNA, INGREZZA, ARISTADA, ZURZUVAE, TRINTELLIX, COBENFY, VRAYLAR, General - Angiography.
Industry payments across AR — which companies pay providers there.
